State Street Holds 4.4% Of Verastem In A Passive Position Measured In September

Verastem expects October financing and cancer-drug revenue to support operations into the first half of 2028.

Share
State Street Holds 4.4% Of Verastem In A Passive Position Measured In September

State Street reported a 4.4% passive stake in Verastem, which develops and sells cancer medicines, in an SEC ownership disclosure filed Tuesday. The position comprised 4,020,999 common shares as of September 30, rather than a purchase established on the filing date.

A Passive Position, Not A Control Bid

State Street certified that the holding arose from its ordinary business activities and was not intended to change or influence Verastem's control.

The company reported shared voting power over 3,933,505 shares, with no sole voting power. It also reported shared power to dispose of 4,020,999 shares.

October Funding Supports The Cancer Pipeline

Verastem raised capital after mixed third-quarter results. Management expects the October financing, together with CO-PACK revenue, to fund operations into the first half of 2028.

Its commercial product, AVMAPKI FAKZYNJA CO-PACK, pairs avutometinib capsules with defactinib tablets. Approved in the United States, it treats adults whose KRAS-mutated recurrent low-grade serous ovarian cancer has previously received systemic therapy. Specialty pharmacies and distributors sell the treatment; its first full seven months on the market generated $30.9 million in net product revenue in 2025.

Verastem's medicines target cancers driven by RAS/MAPK, a cell-signaling pathway involved in tumor growth. Its development pipeline includes VS-7375, an oral KRAS G12D inhibitor licensed from GenFleet Therapeutics, in an early-stage trial involving pancreatic, lung and colorectal cancers, as well as preclinical programs.

Two doses of VS-7375 tested on their own cleared testing without toxicities that limited dosing. The program moved into combination testing with cetuximab.

Recent Gains Meet A Longer Decline

As of Tuesday's original report, Verastem shares had gained 39.17% over 90 days, while the five-year shareholder return was down 75.11%.

Verastem's market capitalization was $1.1 billion at 9:38 a.m. ET Tuesday. The September ownership position and management's funding outlook provide separate context for a company balancing commercial sales with continued drug development.

Sources

More on Verastem

All Verastem (VSTM) coverage →